| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
140,990,000 |
| Market
Cap: |
73.88(M) |
| Last
Volume: |
2,041,307 |
Avg
Vol: |
1,748,484 |
| 52
Week Range: |
$0.2971 - $1.74 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Sangamo BioSciences is a clinical-stage genomic medicine company focused on translating science into medicines. Co.'s clinical-stage product candidates are: Isaralgagene civaparvovec (ST-920), which is Co.'s wholly-owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, which is Co.'s zinc finger nuclease gene-edited cell therapy product candidate for the treatment of sickle cell disease; TX200 for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and Giroctocogene fitelparvovec (SB-525), which is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
6,000,000 |
6,500,000 |
| Total Sell Value |
$0 |
$0 |
$3,000,000 |
$5,657,240 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
3 |
| End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kolchinsky Peter |
Former 10% Owner |
– – – |
2014-05-28 |
4 |
S |
$13.42 |
$1,996,952 |
D/D |
(148,689) |
4,168,834 |
|
- |
|
| Kolchinsky Peter |
Former 10% Owner |
– – – |
2014-05-27 |
4 |
S |
$13.55 |
$3,570,473 |
D/D |
(263,437) |
4,317,523 |
|
- |
|
| Ando Dale G |
VP, Therapeutic Dev. & CMO |
• – – |
2014-05-27 |
4 |
AS |
$13.57 |
$203,531 |
D/D |
(15,000) |
98,377 |
|
- |
|
| Ando Dale G |
VP, Therapeutic Dev. & CMO |
• – – |
2014-05-27 |
4 |
OE |
$3.45 |
$55,230 |
D/D |
15,000 |
100,377 |
|
- |
|
| Kolchinsky Peter |
Former 10% Owner |
– – – |
2014-05-23 |
4 |
S |
$13.27 |
$684,713 |
D/D |
(51,597) |
4,580,960 |
|
- |
|
| Kolchinsky Peter |
Former 10% Owner |
– – – |
2014-05-22 |
4 |
S |
$13.51 |
$764,537 |
D/D |
(56,396) |
4,632,557 |
|
- |
|
| Lanphier Edward O Ii |
President & CEO |
• • – |
2014-05-15 |
4 |
AS |
$13.14 |
$328,543 |
I/I |
(25,000) |
1,541,054 |
|
- |
|
| Kolchinsky Peter |
Former 10% Owner |
– – – |
2014-05-13 |
4 |
S |
$13.12 |
$735,305 |
D/D |
(56,060) |
4,688,953 |
|
- |
|
| Kolchinsky Peter |
Former 10% Owner |
– – – |
2014-05-12 |
4 |
S |
$13.01 |
$386,330 |
D/D |
(29,659) |
4,745,013 |
|
- |
|
| Wolff Henry Ward |
Exec VP & CFO |
• – – |
2014-05-12 |
4 |
AS |
$12.85 |
$192,756 |
D/D |
(15,000) |
224,347 |
|
- |
|
| Wolff Henry Ward |
Exec VP & CFO |
• – – |
2014-05-12 |
4 |
OE |
$7.73 |
$100,490 |
D/D |
13,000 |
239,347 |
|
- |
|
| Kolchinsky Peter |
Former 10% Owner |
– – – |
2014-05-08 |
4 |
S |
$12.39 |
$1,032,587 |
D/D |
(83,300) |
4,774,672 |
|
- |
|
| Kolchinsky Peter |
Former 10% Owner |
– – – |
2014-05-07 |
4 |
B |
$12.09 |
$431,870 |
D/D |
35,736 |
4,857,972 |
2.44 |
- |
|
| Kolchinsky Peter |
Former 10% Owner |
– – – |
2014-05-07 |
4 |
B |
$11.71 |
$557,989 |
D/D |
47,564 |
4,822,236 |
2.44 |
- |
|
| Gregory Philip D |
SVP of Research & CSO |
• – – |
2014-05-01 |
4 |
AS |
$13.68 |
$205,179 |
D/D |
(15,000) |
109,347 |
|
- |
|
| Gregory Philip D |
SVP of Research & CSO |
• – – |
2014-05-01 |
4 |
OE |
$3.45 |
$84,840 |
D/D |
15,000 |
124,347 |
|
- |
|
| Kolchinsky Peter |
Former 10% Owner |
– – – |
2014-04-30 |
4 |
B |
$13.29 |
$1,674,679 |
D/D |
124,500 |
4,774,672 |
2.44 |
- |
|
| Kolchinsky Peter |
Former 10% Owner |
– – – |
2014-04-28 |
4 |
B |
$13.29 |
$995,014 |
D/D |
74,844 |
4,650,172 |
2.44 |
- |
|
| Larson John William |
Director |
– • – |
2014-04-28 |
4 |
S |
$13.48 |
$134,786 |
D/D |
(10,000) |
218,160 |
|
- |
|
| Larson John William |
Director |
– • – |
2014-04-28 |
4 |
OE |
$5.66 |
$56,600 |
D/D |
10,000 |
228,160 |
|
- |
|
| Ando Dale G |
VP, Therapeutic Dev. & CMO |
• – – |
2014-04-28 |
4 |
S |
$13.63 |
$204,532 |
D/D |
(15,000) |
97,015 |
|
- |
|
| Ando Dale G |
VP, Therapeutic Dev. & CMO |
• – – |
2014-04-28 |
4 |
OE |
$3.45 |
$55,230 |
D/D |
15,000 |
99,015 |
|
- |
|
| Kolchinsky Peter |
Former 10% Owner |
– – – |
2014-04-25 |
4 |
B |
$13.63 |
$2,262,779 |
D/D |
166,000 |
4,575,328 |
2.44 |
- |
|
548 Records found
|
|
Page 22 of 22 |
|
|
0.04 (6.83%) 
